UnitedHealth's Q2 2026 operating earnings rose 55% on flat revenue as the medical care ratio fell to 86.7% from 89.4%, driven by repricing, 1.6 million fewer members and $860 million of favorable prior-period reserve development — but full-year guidance of 88.1% MCR signals the quarter is not the run rate.
Revenue
$112.0B
+0.4% YoY
Net income
$5.5B
+61.0% YoY
Diluted EPS
$6.04
+61.5% YoY
Operating margin
7.1%
Profits nearly doubled on flat revenue as UnitedHealth shrank its way back to margin
UnitedHealth Group's second quarter of 2026 is the clearest evidence yet that the company's response to its 2024-2025 cost crisis was to stop chasing membership and start repricing what it already had. Revenue was essentially flat — $112.0 billion against $111.6 billion a year earlier, growth of 0.4% — but earnings from operations rose 55% to $8.0 billion and diluted earnings per share went from $3.74 to $6.04.
None of that came from selling more insurance. UnitedHealthcare covered 48.5 million medical members at June 30, 2026, down 1.59 million (3.2%) from a year earlier, including 785,000 fewer Medicare Advantage members and 710,000 fewer Medicaid members. The profit recovery came almost entirely from the gap between what UnitedHealth charges and what it pays out narrowing — and, as detailed below, from a sizeable release of money it had previously set aside for claims.
Operating margin is earnings from operations divided by revenue — the share of every dollar of revenue left after paying medical claims and running the business, before interest and tax. The medical care ratio (MCR) is the share of premium dollars paid straight back out as medical costs; UnitedHealth defines it as medical costs divided by premium revenue. For a health insurer the MCR is the single most-watched number: everything below it — administration, interest, tax and profit — has to fit in what's left.
What actually moved the MCR
The MCR fell 2.7 percentage points, from 89.4% to 86.7%. On roughly $87.0 billion of quarterly premium revenue, each point of MCR is worth about $870 million of pre-tax earnings, so this one ratio explains the bulk of the $2.8 billion swing in operating earnings.
The filing is specific about the components. Medical costs fell 4.1% to $75.4 billion "primarily due to fewer people served across UnitedHealthcare and Optum Health and favorable prior period reserve development." On the MCR itself, management attributes the improvement to "favorable prior period reserve development, affordability and medical cost management initiatives, and pricing trends."
Two of those three are durable; one is not.
Pricing and membership mix are durable. UnitedHealth repriced 2026 Medicare Advantage and commercial risk plans knowing what 2025 had cost it, and members who wouldn't pay the new price left. Risk-based commercial membership fell 9% to 7.66 million while fee-based (administrative-services-only, where the employer carries the claims risk and UnitedHealth just administers) grew 3% to 22.27 million. That mix shift lowers reported revenue but takes medical risk off the books.
Reserve development is not durable. See below.
The reserve release — a real caveat on earnings quality
Health insurers book an estimate of claims that have been incurred but not yet reported to them. When those claims come in cheaper than booked, the difference is released back into earnings. UnitedHealth's Q2 earnings release quantifies it: the MCR "was affected by $860 million of net favorable prior period development, with the majority related to 2026 dates of service."
The 10-Q's reserve roll-forward gives the six-month picture: $1,250 million of favorable prior-year development in the first half of 2026 against just $320 million in the first half of 2025 — a $930 million year-over-year swing, attributed to "a favorable respiratory illness season along with various other individually insignificant factors."
Put plainly: roughly a full percentage point of the 2.7-point MCR improvement is money set aside last period and not needed, not a lower cost of care this period. Two things soften that:
The release is mostly against 2026 dates of service, per the earnings release — meaning the company over-reserved a few months ago, not years ago. That is a better sign than releasing stale multi-year reserves, because it says current-year claims are running below plan.
Medical costs payable ended the period at $38.9 billion against $39.3 billion at the start of the year, on roughly flat premium — a modest decline in the cushion, not a dramatic one.
Still, if an investor strips the incremental $860 million out of Q2, operating earnings are closer to $7.1 billion and the year-over-year improvement is roughly 38% rather than 55%. That is still a large recovery; it is just a materially different one.
Cost trend itself has not gone away
The same MD&A paragraph that explains the improvement also names what is still working against it: "elevated medical cost trend which remains above historical levels and continues to be affected by higher provider reimbursement under the No Surprises Act and increased service and coding intensity in commercial."
That is worth unpacking, because it identifies two structural pressures rather than a passing one:
The No Surprises Act is the US law that bars out-of-network providers from billing patients directly for the balance of a bill; disputes go to arbitration between insurer and provider instead. UnitedHealth is saying those arbitration outcomes are settling at higher provider reimbursement than before.
Coding intensity in commercial means providers are documenting patients as sicker and billing at higher-acuity codes, which raises what the insurer owes per encounter even when the volume of encounters is unchanged.
Neither reverses because UnitedHealth prices better. Both are why full-year guidance (below) assumes an MCR well above the 86.7% just printed.
Costs of running the business went the wrong way
The operating cost ratio — administrative and overhead spend as a share of revenue — rose to 12.7% from 12.3%, an increase management attributes to "investments in people, process and technology to drive improved consumer and care provider experiences and greater operating efficiencies, and business mix."
This is a deliberate trade, and it partially offsets the medical-cost win: on $112 billion of revenue, 0.4 points of operating cost ratio is roughly $450 million a quarter. It is also the line most exposed to the long list of affordability and prior-authorization commitments the company detailed alongside results — eliminating 30% of prior approval volume by end-2026, expanding Gold Card exemptions, a transparent fee-based pharmacy model, accelerated payments to 1,500 rural hospitals. Those reduce friction for providers; they do not reduce UnitedHealth's own cost to serve.
Segments: Optum Health does the heavy lifting on the Optum side
Segment
Q2 2026 revenue
Q2 2025 revenue
Q2 2026 operating earnings
Q2 2025 operating earnings
Operating margin 2026 / 2025
UnitedHealthcare
$86,017M
$86,103M
$3,942M
$2,075M
4.6% / 2.4%
Optum Health
$23,472M
$24,725M
$1,190M
$429M
5.1% / 1.7%
Optum Insight
$5,402M
$5,232M
$1,369M
$1,205M
25.3% / 23.0%
Optum Rx
$38,292M
$38,459M
$1,490M
$1,441M
3.9% / 3.7%
Segment revenues include sales between segments and so sum to more than consolidated revenue; $39.6 billion of intersegment eliminations bridges the difference. Prior-year Optum Health and Optum Insight figures were recast because Optum Financial, including Optum Bank, moved from Optum Health to Optum Insight on January 1, 2026.
UnitedHealthcare roughly doubled operating earnings on flat revenue — the whole story is the MCR. Revenue was held down by the membership contraction and by the company's voluntary pledge to rebate 2026 profits on its individual Affordable Care Act plans to roughly one million members, offset by pricing actions including higher Medicaid rates.
Optum Health is the most improved business in the quarter: earnings of $1,190 million against $429 million, with margin going from 1.7% to 5.1% even as revenue fell 5%. This is the unit that took the 2025 damage — it delivers care under value-based arrangements, where Optum is paid a fixed amount per patient and keeps the difference if care costs less, so it absorbs cost overruns directly. The revenue decline is a consequence of the fix: fewer patients served under value-based arrangements (Optum Health served about 93 million people versus 95 million) plus divestitures. Earnings rose on "cost management, increased favorable reserve development and the net decrease in loss contract reserves" — a loss contract reserve is money booked against contracts expected to lose money, and releasing $50 million of it in the quarter flatters the comparison — "partially offset by continued elevated medical cost trends."
Optum Rx is the soft spot. Adjusted scripts fell to 387 million from 414 million (-6.5%) because fewer UnitedHealthcare members means fewer prescriptions to fill; earnings rose only 3%, with growth in specialty pharmacy offsetting the volume loss. This is the clearest illustration of the cost of shrinking the insurance book: it drags the pharmacy business with it.
Optum Insight's reported numbers are noisy. Quarterly earnings grew 14% on business services growth and higher investment income, but the six-month figure is down 2%, because the first half carried a $400 million contribution to the United Health Foundation (funded by the cash gain on selling an Optum Insight business) against a $524 million year-to-date gain on portfolio divestitures in the same segment. Both belong in any assessment of the half, but neither says much about run-rate performance.
Cash generation improved more than earnings did
First-half cash from operations was $19,964 million against $12,644 million a year earlier, a $7.3 billion improvement — and the company reported $11.1 billion of operating cash flow in Q2 alone, 1.9 times net income. For an insurer, operating cash running well ahead of net income usually means claims are being paid out more slowly than premium comes in; here, payments for prior-year claims actually rose to $32.5 billion from $29.0 billion in the first half, so the improvement is coming from the earnings recovery rather than from stretching payables.
Capital returns continued: the board raised the dividend to an annual rate of $9.28 from $8.84 in June 2026, and the company settled forward contracts repurchasing 6.4 million shares at an average $312.73 during the first half, with a $2.0 billion liability paid July 1. Debt-to-capital was 41.2% at quarter end. UnitedHealth also closed a $3.0 billion health-sector acquisition on July 2, 2026, paying $1.5 billion in cash with the balance due within a year.
Two unquantified overhangs
Neither of these affected the quarter's numbers, but both are real and neither can be sized from the filing:
The IRS transfer-pricing challenge. On March 6, 2026, UnitedHealth received Notices of Proposed Adjustment covering intercompany transfer pricing with a foreign subsidiary for tax years 2017-2020. The IRS "is seeking to significantly increase taxable income for each of the applicable periods and could also seek similar adjustments for subsequent years after 2020." The company disagrees and intends to contest it, and believes its existing reserves are adequate. No dollar figure is disclosed.
The DOJ False Claims Act case on Medicare risk-adjustment coding, running since a 2011 whistleblower complaint. A court-appointed Special Master recommended summary judgment in UnitedHealth's favor on all remaining claims in March 2025; the DOJ moved to reject that report in April 2025. The company says it "cannot reasonably estimate the outcome."
Note also that the effective tax rate rose to 18.6% from 12.5%, because Q2 2025's rate was artificially low — with depressed pre-tax income, fixed tax benefits had outsized proportional effect. Pre-tax earnings actually grew 70.7% year over year, faster than the 61.0% growth in net earnings; the tax line was a headwind, not a help, to the reported recovery.
Takeaway: The 2.7-point drop in the medical care ratio is the entire quarter, and about a point of it is reserve releases rather than lower care costs — management's own full-year MCR guidance of 88.1% ±25bps, 1.4 points worse than the 86.7% just reported, is the honest statement that this quarter's ratio is not the run rate.
Guidance and our read
Management raised full-year 2026 guidance alongside these results:
2026 full-year guidance
Figure
Diluted EPS
$18.45 - $18.95
Adjusted diluted EPS
$19.50 - $20.00
Net earnings to UNH shareholders
> $16,750M
Medical care ratio
88.1% ± 25 bps
Cash flows from operations
~$24,000M
Tax rate
~18.5%
Share repurchase
At least $5,000M
UnitedHealthcare operating earnings
> $12,000M
Optum operating earnings
> $13,450M
The internal arithmetic of that guidance is the most useful forward-looking information in the release. First-half adjusted EPS was $13.61; the midpoint of full-year adjusted guidance, $19.75, implies roughly $6.14 in the second half — below the $6.38 UnitedHealth just earned in a single quarter. Similarly, first-half MCR was 85.3%, so a full-year 88.1% requires a second-half MCR near 91%.
Management is therefore explicitly guiding to a worse second half, which is partly seasonal (medical utilization and Part D benefit design push costs into later quarters) and partly an acknowledgement that first-half reserve releases will not repeat. The guidance also assumes cash flow of about $24 billion for the year against $20 billion already banked in the first half.
Our read: the operational fix is real and is working faster on margin than on revenue. UnitedHealth has traded 1.6 million members and the pharmacy volume attached to them for roughly 2.5 points of operating margin, and the Optum Health turnaround — from a 1.7% to a 5.1% quarterly margin — was the specific thing that had to happen for the story to change. The open question is what happens when the repricing cycle is finished and the company has to grow again into a market where the No Surprises Act and commercial coding intensity are still lifting the cost of every covered life. The second-half guide embeds a visibly conservative MCR; if that conservatism proves unnecessary, the upside lands in Q4. If it proves necessary, it will be because cost trend reasserted itself, and the 2026 pricing cycle will have bought one year of relief rather than a reset.